NanoKnife and immunotherapy for stage IV colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining a procedure called NanoKnife (which uses electrical pulses to destroy liver tumors) with immunotherapy to see if it helps people with colorectal cancer that has spread to the liver. It is for patients whose liver tumors cannot be removed by surgery and have stayed stable on chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to your liver, and at least one liver tumor is between 2 cm and 3.2 cm and can be treated with NanoKnife.
- Your primary colorectal tumor has been surgically removed.
- Your liver tumors were reviewed by a team of specialists and cannot be surgically removed.
- You have tried chemotherapy but it did not make your liver tumors removable by surgery.
- Your liver tumors have been stable on your current cancer treatment for at least 2 months.
- You have a specific type of tumor that is not MSI-High (a genetic marker).
- You have one of two specific immune system types called HLA-A1 or HLA-A2.
- You do not have active autoimmune disease, heart rhythm problems (except controlled atrial fibrillation), or cirrhosis.
- You are not pregnant and have no major other serious illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.
This trial tests whether adding the drug IP-001 to tumor ablation (microwave or irreversible electroporation) helps control colorectal cancer that has spread to the liver. The goal is to find the best dose and see how the immune system responds.
This trial tests a combination of precise radiation to liver or lung tumors plus immunotherapy for people with advanced colorectal cancer that cannot be surgically removed. It aims to see if this approach can help control the cancer.
This trial tests a combination of treatments for colorectal cancer that has spread to the liver and cannot be surgically removed. It uses an injected oncolytic virus, targeted radiation, chemotherapy, and immunotherapy to attack the tumors from multiple angles.
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
This trial tests a treatment called IRE (a type of non-thermal ablation) for colorectal cancer that has spread to the liver. It aims to see if IRE can safely and effectively treat these liver tumors, offering a possible option for patients who may not be candidates for surgery or thermal ablation.
Hear when a new Liver Metastasis Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.